Halozyme Therapeutics Inc Cash Flow-to-Debt Ratio
Halozyme Therapeutics Inc cash flow-to-debt ratio. Halozyme Therapeutics Inc (HALO) has a Cash Flow-to-Debt Ratio of 0.10x as of September 2025, meaning its operating cash flow of $178.60 Million could theoretically repay 0% of its total liabilities ($1.72 Billion) in one year. Check Halozyme Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Halozyme Therapeutics Inc (2001–2024)
Cash flow-to-debt ratio of Halozyme Therapeutics Inc from 2001 to 2024. Historical debt coverage capacity for Halozyme Therapeutics Inc across 24 annual periods. Check Halozyme Therapeutics Inc (HALO) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Halozyme Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2001–2024)
Halozyme Therapeutics Inc cash flow-to-debt ratio by year from 2001 to 2024. Year-by-year debt coverage analysis for Halozyme Therapeutics Inc. For the full cash flow conversion analysis, see cash efficiency ratio of Halozyme Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.28x | $479.06 Million | $1.70 Billion | ▲ +19.6% |
| 2023 | 0.24x | $388.57 Million | $1.65 Billion | ▲ +64.0% |
| 2022 | 0.14x | $240.11 Million | $1.67 Billion | ▼ -56.5% |
| 2021 | 0.33x | $299.44 Million | $907.48 Million | ▲ +155.2% |
| 2020 | 0.13x | $55.45 Million | $428.88 Million | ▲ +171.8% |
| 2019 | -0.18x | $-85.42 Million | $474.11 Million | ▲ +30.3% |
| 2018 | -0.26x | $-49.50 Million | $191.36 Million | ▼ -160.1% |
| 2017 | 0.43x | $134.05 Million | $311.58 Million | ▲ +351.1% |
| 2016 | -0.17x | $-50.38 Million | $294.00 Million | ▲ +35.9% |
| 2015 | -0.27x | $-37.08 Million | $138.79 Million | ▲ +29.9% |
| 2014 | -0.38x | $-47.52 Million | $124.62 Million | ▲ +5.9% |
| 2013 | -0.41x | $-49.34 Million | $121.78 Million | ▲ +45.9% |
| 2012 | -0.75x | $-64.33 Million | $85.87 Million | ▼ -19.6% |
| 2011 | -0.63x | $-34.35 Million | $54.86 Million | ▲ +2.1% |
| 2010 | -0.64x | $-45.39 Million | $70.99 Million | ▼ -11.9% |
| 2009 | -0.57x | $-40.15 Million | $70.25 Million | ▲ +1.1% |
| 2008 | -0.58x | $-35.37 Million | $61.18 Million | ▼ -17791.0% |
| 2007 | 0.00x | $-147.66K | $45.69 Million | ▼ -101.1% |
| 2006 | 0.31x | $7.08 Million | $23.01 Million | ▲ +105.5% |
| 2005 | -5.64x | $-13.00 Million | $2.30 Million | ▼ -15.5% |
| 2004 | -4.89x | $-7.72 Million | $1.58 Million | ▼ -268.0% |
| 2003 | -1.33x | $-49.73K | $37.45K | ▲ +75.2% |
| 2002 | -5.35x | $-55.78K | $10.43K | ▲ +48.8% |
| 2001 | -10.45x | $-34.37K | $3.29K | — |